[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.161.216.242. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Evidence-Based Dermatology: Research Commentary
December 2007

Level of Agreement With the British Guidelines for the Use of Biological Therapies for Psoriasis

Arch Dermatol. 2007;143(12):1567-1569. doi:10.1001/archderm.143.12.1567

Question: When, who, and how to prescribe biological therapies for psoriasis in the United Kingdom?

Setting: British Association of Dermatologists (BAD) guideline working group.

Design: The BAD group developed guidelines for the use of biological interventions in psoriasis 2005. They used BAD-recommended methodology and the AGREE (Appraisal of Guidelines for Research and Evaluation) instrument. A literature review was performed by searching EMBASE and Medline (1990–early 2005) for clinical psoriasis trials involving efalizumab, etanercept, and infliximab using an agreed-on protocol. Included manuscripts were scored using the NICE (National Institute for Clinical Excellence) criteria for level of evidence and strength of recommendation. The pharmacology, clinical effectiveness, dosing regimens, and toxicity of the biological agents are reviewed. Three key questions (Which patients should be considered for biological therapy? Who should prescribe biological therapy? and How to prescribe biological therapies?) are answered.

First Page Preview View Large
First page PDF preview
First page PDF preview
×